(R)-N-hydroxy-2-(4-methoxyphenylsulfonamido-N-(prop-2-yn-1-yl))-3-methylbutanamide | 1378928-99-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-N-hydroxy-2-(4-methoxyphenylsulfonamido-N-(prop-2-yn-1-yl))-3-methylbutanamide
• 英文别名: (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-prop-2-ynylamino]-3-methylbutanamide
• CAS: 1378928-99-4
• 化学式: C₁₅H₂₀N₂O₅S
• 分子量: 340.4
• InChiKey: JLXRKMSJFVPFIG-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-[18F]fluoroethylazide 、 (R)-N-hydroxy-2-(4-methoxyphenylsulfonamido-N-(prop-2-yn-1-yl))-3-methylbutanamide 在 copper(ll) sulfate pentahydrate 、 sodium ascorbate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 以55%的产率得到(R)-2-(N-((1-(2-[18F]fluoroethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methoxyphenylsulfonamido)-N-hydroxy-3-methylbutanamide
  参考文献：
  名称：

  A New Class of Highly Potent Matrix Metalloproteinase Inhibitors Based on Triazole-Substituted Hydroxamates: (Radio)Synthesis and in Vitro and First in Vivo Evaluation

  摘要：

  In vivo imaging of MMPs is of great (pre)clinical interest and can potentially be realized with modern three-dimensional and noninvasive in vivo molecular imaging techniques such as positron emission tomography (PET). Consequently, MMP inhibitors (MMPIs) radiolabeled with positron emitting nuclides (e.g., F-18) represent a suitable tool for the visualization of activated MMPs with PET. On the basis of our previous work and results regarding radiolabeled and unlabeled derivatives of the nonselective MMPIs, we discovered a new class of fluorinated MMPIs with a triazole-substituted hydroxamate substructure. These novel MMPIs are characterized by an increased hydrophilicity compared with the lead structures and excellent MMP inhibition potencies for MMP-2, MMP-8, MMP-9, and MMP-13 (IC50 = 0.006-107 nM). Therefore, one promising fluorinated triazole-substituted hydroxamate (30b) was selected and resynthesised as its F-18-labeled version to yield the potential PET radioligand [F-18]30b. The biodistribution behavior of this novel compound was investigated with small animal PET.

  DOI：

  10.1021/jm300199g
• 作为产物：
  描述：

  (R)-tert-butyl 2-(4-methoxyphenylsulfonamido-N-(prop-2-yn-1-yl))-3-methylbutanoate 在 N-甲基吗啉 、 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 (R)-N-hydroxy-2-(4-methoxyphenylsulfonamido-N-(prop-2-yn-1-yl))-3-methylbutanamide
  参考文献：
  名称：

  [EN] COMPOUNDS WITH MATRIX-METALLOPROTEINASE INHIBITORY ACTIVITY
  [FR] COMPOSÉS AVEC ACTIVITÉ INHIBITRICE DE MÉTALLOPROTÉINASE DE MATRICE

  摘要：

  本发明涉及治疗和诊断试剂领域，更具体地涉及一种具有式（I）的化合物，该化合物是基质金属蛋白酶（MMPs）的抑制剂，并且在治疗与之相关的疾病如心血管疾病、炎症性疾病和恶性疾病方面有用。本发明的一个实施例是一种带有18-氟原子的式（I）化合物，具有适用于诊断成像的基质金属蛋白酶抑制活性。本发明还公开了一种包含本发明的基质金属蛋白酶（MMPs）抑制剂或相应标记化合物的制药组合物，适合于哺乳动物管理。此外，本发明还公开了在合成本发明的基质金属蛋白酶（MMPs）抑制剂和诊断成像剂中的中间体。

  公开号：

  WO2013010573A1

文献信息

• [EN] COMPOUNDS WITH MATRIX-METALLOPROTEINASE INHIBITORY ACTIVITY<br/>[FR] COMPOSÉS AVEC ACTIVITÉ INHIBITRICE DE MÉTALLOPROTÉINASE DE MATRICE
  申请人：UNIV MUENSTER

  公开号：WO2013010573A1

  公开（公告）日：2013-01-24

  The present invention relates to the field of therapeutic and diagnostic agents and more specifically to compounds of formula (I) that are inhibitors of matrix-metalloproteinases (MMPs) and are useful in the treatment of diseases related thereto such as cardiovascular diseases, inflammatory diseases and malignant diseases. One embodiment of the invention is a compound of formula (I) labeled with a 18-fluorine atom having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the inhibitors of matrix-metalloproteinases (MMPs) of the invention or the corresponding labeled compounds useful as diagnostic imaging agents of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the inhibitors of matrix-metalloproteinases (MMPs) of the invention and of the diagnostic imaging agents of the invention.

  本发明涉及治疗和诊断试剂领域，更具体地涉及一种具有式（I）的化合物，该化合物是基质金属蛋白酶（MMPs）的抑制剂，并且在治疗与之相关的疾病如心血管疾病、炎症性疾病和恶性疾病方面有用。本发明的一个实施例是一种带有18-氟原子的式（I）化合物，具有适用于诊断成像的基质金属蛋白酶抑制活性。本发明还公开了一种包含本发明的基质金属蛋白酶（MMPs）抑制剂或相应标记化合物的制药组合物，适合于哺乳动物管理。此外，本发明还公开了在合成本发明的基质金属蛋白酶（MMPs）抑制剂和诊断成像剂中的中间体。
• A New Class of Highly Potent Matrix Metalloproteinase Inhibitors Based on Triazole-Substituted Hydroxamates: (Radio)Synthesis and in Vitro and First in Vivo Evaluation
  作者：Verena Hugenberg、Hans-Jörg Breyholz、Burkhard Riemann、Sven Hermann、Otmar Schober、Michael Schäfers、Umesh Gangadharmath、Vani Mocharla、Hartmuth Kolb、Joseph Walsh、Wei Zhang、Klaus Kopka、Stefan Wagner

  DOI：10.1021/jm300199g

  日期：2012.5.24

  In vivo imaging of MMPs is of great (pre)clinical interest and can potentially be realized with modern three-dimensional and noninvasive in vivo molecular imaging techniques such as positron emission tomography (PET). Consequently, MMP inhibitors (MMPIs) radiolabeled with positron emitting nuclides (e.g., F-18) represent a suitable tool for the visualization of activated MMPs with PET. On the basis of our previous work and results regarding radiolabeled and unlabeled derivatives of the nonselective MMPIs, we discovered a new class of fluorinated MMPIs with a triazole-substituted hydroxamate substructure. These novel MMPIs are characterized by an increased hydrophilicity compared with the lead structures and excellent MMP inhibition potencies for MMP-2, MMP-8, MMP-9, and MMP-13 (IC50 = 0.006-107 nM). Therefore, one promising fluorinated triazole-substituted hydroxamate (30b) was selected and resynthesised as its F-18-labeled version to yield the potential PET radioligand [F-18]30b. The biodistribution behavior of this novel compound was investigated with small animal PET.